Corvus Pharmaceuticals, Inc. ( CRVS) Stock. Should you Buy or Sell? $ 1.00
-0.03 (-3.09 %)
Corvus Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | CRVS |
| Price | $1.00 |
| Beta | 0.929 |
| Volume Avg. | $323.05 thousand |
| Market Cap | $46.55 M |
| 52 Week Range | $0.75 - $9.54 |
Corvus Pharmaceuticals, Inc. opened the day at $1.00 which is -3.09 % on yesterday's close. Corvus Pharmaceuticals, Inc. has a 52 week high of $9.54 and 52 week low of $0.75, which is a difference of $8.79. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $46.55 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Corvus Pharmaceuticals, Inc. for $46.55 M, it would take 15 years to get your money back. Corvus Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Corvus Pharmaceuticals, Inc. Stock Forecast - Is Corvus Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -1.273 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Corvus Pharmaceuticals, Inc.
| Price Book Value Ratio | 0.579 | Price To Book Ratio | 0.579 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -1.273 |
How liquid is Corvus Pharmaceuticals, Inc.
| Current Ratio | 5.798 |
| Quick Ratio | 5.627 |
Debt
| Debt Ratio | 0.131 | Debt Equity Ratio | 0.151 |
| Long Term Debt To Capitalization | 0.024 | Total Debt To Capitalization | 0.038 |
Latest news about Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place September 12-14, 2022. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 12.
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer James Rosenbaum - Senior President of Research Conference Call Participants Sean Lee - H.C. Wainwright Operator Good afternoon, and welcome to the Corvus Pharmaceutical Second Quarter 2022 Earnings Conference Call.
Penny stocks insiders are buying right now. The post Best Penny Stocks To Watch In April?
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript
About Corvus Pharmaceuticals, Inc.
Description :
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
